FibroGen (NASDAQ:FGEN) Given “Positive” Rating at Mizuho
Mizuho restated their positive rating on shares of FibroGen (NASDAQ:FGEN) in a research note released on Monday, The Fly reports. They currently have a $72.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $65.00.
Several other equities research analysts have also recently commented on the stock. TheStreet upgraded shares of FibroGen from a d+ rating to a c rating in a research report on Tuesday, August 13th. ValuEngine upgraded shares of FibroGen from a hold rating to a buy rating in a research report on Friday, November 8th. Zacks Investment Research upgraded shares of FibroGen from a hold rating to a buy rating and set a $51.00 price target for the company in a research report on Tuesday, August 13th. Finally, BidaskClub upgraded shares of FibroGen from a sell rating to a hold rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. FibroGen presently has an average rating of Buy and an average target price of $58.33.
Shares of NASDAQ:FGEN traded up $2.01 during trading on Monday, hitting $36.99. 1,002,000 shares of the company’s stock were exchanged, compared to its average volume of 736,316. FibroGen has a 1-year low of $32.33 and a 1-year high of $61.23. The firm has a 50-day moving average price of $38.31 and a two-hundred day moving average price of $41.63. The company has a current ratio of 9.73, a quick ratio of 9.71 and a debt-to-equity ratio of 0.07. The firm has a market cap of $3.09 billion, a P/E ratio of -35.91 and a beta of 1.84.
In related news, CEO Thomas B. Neff sold 39,636 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $44.33, for a total transaction of $1,757,063.88. Following the completion of the transaction, the chief executive officer now owns 2,356,578 shares in the company, valued at $104,467,102.74. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Christine Chung sold 5,625 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $34.74, for a total transaction of $195,412.50. Following the transaction, the senior vice president now owns 145,253 shares of the company’s stock, valued at approximately $5,046,089.22. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 92,381 shares of company stock valued at $3,839,495. Corporate insiders own 8.96% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of FGEN. Captrust Financial Advisors acquired a new position in FibroGen during the second quarter valued at approximately $90,000. US Bancorp DE grew its holdings in FibroGen by 79.7% during the second quarter. US Bancorp DE now owns 2,172 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 963 shares during the period. Usca Ria LLC acquired a new position in FibroGen during the third quarter valued at approximately $123,000. Convergence Investment Partners LLC acquired a new position in FibroGen during the third quarter valued at approximately $137,000. Finally, Nisa Investment Advisors LLC grew its holdings in FibroGen by 729.8% during the third quarter. Nisa Investment Advisors LLC now owns 3,900 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 3,430 shares during the period. Hedge funds and other institutional investors own 69.03% of the company’s stock.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Read More: Trading based on a resistance level
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.